Member Info for 2017andonwards

Feeks, It is small beer, it is in consequential, particularly when you retain 1 million purchased shares. However, this is not the point. Not every investor will know that our FD, Alex Abrey, holds that many shares. Many will just view the scale with either fear or scepticism and this in turn encourages sales of shares. They do say, follow the trend and also when a director sells, so should you. The transaction was niave. the Company needs to repair the share price damage and quick. how will they do that?

Before they execute actions such as these and even allowing for their own private and personal circumstances, they should sit together as a BoD and discuss the potential consequences of such an action. If they feel the market will react negatively then they need to protect that reaction with an effective 'band aid' to the same. Equally, they might have taken internally to enable Alex to retain the option exercised without the need for a sale. They must think about their actions in specific regards to the share price and it is evident to me over time that they do not do this. As has been posted, having invested in creating momentum (Proactive and Make It Big In London) why go and puncture the same for a few thousand pounds net of tax? Why do so as an officer of the Company? Why do so when (presumably) you want your share price as high as possible relative to operational value? It makes no sense to me. I fail to understand how such a basic error is made when you are effectively custodian of the share price and therefore the value of the Company. What message has Alex Abrey sent to the market with this action? The Company appears to have great solutions and technology that satisfies global agro-chemical issues and hopefully more. Global businesses (Sipcam and Eastman) have come on board to commercialise and endorse the same. Bayer are due soon with revenue contributions in 2018 (according to Eden). In my opinion, Eden needs to review how and what they communicate, what the ramifications are of the same, what does the market need for understanding and confidence, what message ongoing does Eden want to be sending an specifically, they should condition the market to appreciate and understand the value of the Company, today, so that this silly recurring episode of sales hitting the share price can disappear once and for all and so that Eden can have a more stable share price and share register at a fair and more representative value. Eden>>>> What is the considered value of the business today?

As at 1:40pm, �55k purchased, �20k sold. Surely the price should be........UP!

There has been quite a lot of £15,000+ orders of late, inclusive of this morning. The MM's appear to be taking their chances with the smaller value sellers which to me, seems to misrepresent what appears to me to be going on, I people acquiring stock

Feeks "This is on a merry little run. Just a change of sentiment me thinks" I think the sentiment was improved when the Company finally engaged in some long overdue communications, outside of the RNS channel. So the "Make It Big In London" piece and the Proactive film and subsequent newspaper article. Simply sharing information, educating people and delivering it direct from the Company direct is all about widening the story, understanding and sentiment. People feel happier and more secure when companies do this. Let us hope that Eden hasn't closed this door and we see some more soon and or relevance.

https://www.theguardian.com/environment/2018/apr/27/eu-agrees-total-ban-on-bee-harming-pesticides https://www.bloomberg.com/news/articles/2018-04-27/eu-states-agree-to-widen-ban-on-pesticides-linked-to-bee-health I assume this to be a good opportunity for Eden and their professional help to capitalise on this announcement and further vocalise the developments of a British company in delivering natural solutions to compete against traditional pesticides, herbicides and insecticides. Furthermore, this is probably, hopefully, just an initial step by the EU on a larger scale attack against harmful chemical products that would naturally lead companies to either/and 1)escalate their R and D 2) Seek out alliances with companies who are further advanced in non-chemical deliverables 3) buy companies that offer 2) Great News for Eden

What might we expect in the next two weeks? So during the last two weeks, after much resistance to investor communications, Eden finally broke their own mould and delivered through two films and two articles. The result of the same is that retail investors responded, to some degree and the share price is now 50% higher than it was. Delivering investor communications (ideally through a considered plan) alongside an operational plan, will take your investor base (and new investors) on a journey with you. If you give them transport, they will travel! So having dipped their toe in the water, will Eden deliver any RNS's to accompany or support the same in the coming weeks? If so, what might they be? Perhaps 1) CEO and Chairman first share purchases if they are not in a closed period? 2) News on a US distributor as mentioned by Sean in the Proactive video? 3) An update on the collaboration deliverables with Sipcam? The Proactive article said we are 'very far advanced' 4) Totally speculative, but if 'very far advanced' morphed into an imminent RNS, might Sipcam then put someone on the BoD, as is their right to do so under the terms of the deal struck 5) News on Bayer or Terpene Tech? Possibly a bit further off, but who knows as they are already (arguably) overdue. So milestone payments and an indication of the size of the markets they are targeting. Are Bayers 4 intended launches new products OR ARE THEY improvements and replacements for existing retail products on sale. If the latter, both could advise the market of the current market share thus indicating the realistic potential for these New Product Launches (sort of) 6)More communications and if so, what and why? I always ask myself why companies are communicating, what is their strategy with the same, what is the reason for doing so and where (internally) might they be targeting the share price. I don't know why Eden is now communicating and what the sudden change of heart is for this. The Chairman's preliminary results statement said we are 'at an inflexion point'. Does this indicate imminent announcements and hence the communication leading into the same? Also, I have no idea what, if any, their communication strategy is, but might they reveal this soon? I'd be disappointed if we didn't see worthy news in the coming weeks.

I can't see that Eden has mortgaged its future at all. In fact, the future for Eden looks massive, if Eden can progress without a bid coming in and if management and partners can move forward progressively. I believe that if Eden monitises it's encapsulation using another's active ingredients blended with Eden's and keeps product x on patent or/and makes it more efficient then the sharks may start circling because that will be a development of global proportions in Eden's target markets. Apparently, Sipcam is 'very far advanced' according to the 'This is Money's article!!!!!!!

Cont'd POSITIVE BREAKTHROUGH NEARS Eden's full year results {20 Mar) revealed a revenue leap to �1.9m (2016: �0.4m), despite a testing southern European growing season for its fungicidal products, flowing through to a significantly lower underlying pre-tax loss of �1.lm (2016: �1.9m); Eden also closed the year with �3.7m of cash in the bank. For 2018, Shore Capital's Phil Carroll forecasts a sales surge to �3.l m, ahead of �4m and �5.7m in 2019 and 2020 respectively, while the analyst's projections point to a breakthrough into positive EBITDA of �100,000 in 2019. SHARES SAYS: 1' Patient micro cap punters should pocket Eden at 8.25p for exciting growth prospects. (JC) BROKER SAYS: n /a 50 I SHARES I 29 March 2018

Here is the full article below from Shares Magazine. Focal points are Bayer and an eventual bid from Sipcam not out of the question. Eden Research to yield a rich harvest Cultivate a position in the agrochemicals play Under-the-radar Eden Research (EDEN:AIM), whose backers include Livingbridge UK Micro Cap Fund (GB00BV9FVS80) and Artemis Alpha Trust (ATS), looks an attractive proposition. A provider of breakthrough 'natural microencapsulation technologies' and agrochemicals, the AIM company is shifting from a development to a lucrative commercialisation phase, with strong growth set to continue in 2018 driven by new regulatory approvals. ENCAPSULATING EDEN Eden provides sustainable solutions for crop protection, animal health and personal care. Significant investment in intellectual property and registrations has created a competitive advantage in a global agrochemicals industry increasingly shifting towards biological products. The Cirencester-based concern's encapsulation technology, known as Sustaine and currently licensed to Bayer Animal Health in North America, is used in markets such as crop protection, animal and human healthcare . Like humans and animals, plants have developed defences against pests and disease. Among their defences are essential oils containing active molecules (terpenes), which help them combat insect predators and disease. Sustaine encapsulates these active molecules in particles that slow their release over days. This not only ensures better levels of control, but also improves the effectiveness of existing products used for plant protection such as pesticides and biocides. MAKING GRAPE PROGRESS Excitingly, the AIM minnow's first fungicide product Mevalone, which targets Botrytis (grape rot), is approved for sale in 10 nations including the top three wine producers {Italy, France, Spain). Further approvals are expected in 2018 with applications for registration being progressed in countries including the US and Australia. Eden has a second plant protection product, a nematicide named Cedroz, which targets soil-dwelling pests. This is on course for launch in 2019 and CEO Sean Smith says it has potentially a far greater market opportunity than Mevalone. Last summer Sipcam, an Italian multinational that specialises in making and marketing agrochemicals, invested �2.2m for a 9.9% stake in Eden. The pair have inked a number of commercial agreements, giving Eden's agrochemicals and technologies credibility, while an eventual bid from the family -owned Sipcam is far from out of the question.

Here is the Proactive one which people have been talking about https://www.youtube.com/watch?v=ZxE3GNBL_IY Here is the London Live short film which also validates Mevalone in Chablis and Champagne (Epernay) http://www.londonlive.co.uk/programmes/making-it-big-in-london

cuppat, "and by then 2020 the whole picture changes with the opening up of revenue streams from Eastman and Bayer" Isn't Bayer income forecast for later this year?

WKevjw, A lot of it is to do with the negative effects and impacts of pesticides and the move to wards bio control products which of course Eden would satisfy. New patent application by Eden in America, 4/1/2108 http://images2.freshpatents.com/imageviewer/-p20180000071 Supersonico has subsequently provided a mass of commentary, quotes and further links to accompany this He/she also posted this link https://www.youtube.com/channel/UC7H8J3c_ZhH6unfiJWEMEKg. It is a short 3 1/2 minute listen and it is worth listening too. Supersonico picked up that Hardman and co have just started following Eden on Twitter so it looks like a possible new interest or maybe more? You can watch some of their other short films too via the same link. I watched Investor Forums and Investor Engagement Programmes. Maybe just register yourself on ADVFN to get full visibility.

Tonypeters, I don't know if you read ADVFN, but if you don't, do go and read some of Supersonico's research. You might well find it interesting!

Tonypeters "In that case it really is not necessary for you to continue to make posts on open public bulletin boards about your suggested 'way forward'. It seems an odd thing to do." I don't see this as odd at all. I agree it would be if Eden were making plausible efforts to address what I suspect is likely a huge gap in value and market cap, but they are not. The 'market' is not buying Eden stock in any meaningful way and Eden needs to address this. If they do not, then the climb for their share price will become all the harder and maintaining the rise will be the same. I view part of the gap between likely true value and market cap as down to a 1) lack of market confidence in Eden 2) lack of proper understanding of Eden 3) lack of realisation of commercial success by Eden 4) lack of true communication and explanation by Eden 5) a complex subject not simplified for all through communication 6) lack of understanding of pipeline penetration to be delivered by Eden partners I could probably add others. The reason I 'continue to make posts on a public forum' is that it is just that. A place to discuss things and you cannot discuss things with Eden or Powerscourt because generally speaking, they do not make themselves that available or broaden shareholders and potential investors knowledge in Eden Plc. A static share price warrants a closer look, commentary, question and more. To not do so is in my opinion, foolish. Eden has been dead money for two years plus so this discussion is very valid.

Tonypeters, With all due respect, I didn't work for SNRP and I wasn't responsible in any way shape or form, for their operational activities, contract negotiations, P and L. I was asked to help them deliver their investor communications and that's what I did, no ramp.I helped them tell their story. It is no different with any PR firm working for a listed Company. Are they to be responsible for a Company's demise? I think not. It changes nothing in regards to Eden. Do we think Eden will go south? Their story still needs telling by them with someone whoever that someone may be. Powerscourt would be a good start as their chosen partner.

Tony Peters, I have done this work in the past and distributed through Proactive Investors. One of the top 5 PR firms in the City was king enough to be very complimentary, but also told me that the PR firms would never let me in through fear of changing the status quo and thus protecting their effective subscription income. Powerscourt might be on �3-�4k per month, but what have we seen in return for this. Marcus Stuttard, Head of Aim and his colleague on the day were also very complimentary about 'the plan'. AIM will not execute it directly or make Investor communications regulatory as with brokers because they see it as a conflict of interest and the potential for promoting stocks which is not their role. Some 70% of the circa 1,000 listed companies on AIM sit below a market cap of �50 million. This sum also happens to be an entry point for many institutions. Institutions are governed by their investment rules/criteria. The BoD at Eden are well aware of me. Below is a link as an example of how I deliver film content. Everything is pre-prepared, structured with a start, a middle and an end, jargon free, subjects made to be approachable and understood, encourages a 'call to action' which is determined by the viewer, not instructed by the subject. The written plaudits collected, film views and share price reaction suggest it works extremely well. Naturally, it is up to the Company (Eden) to deliver on a commercial basis because the execution of a Communications Plan is about how to best tell the story so that your subject audience understand it and buys in where appropriate. http://www.proactiveinvestors.co.uk/companies/stocktube/1368/strategic-natural-resources-a-really-compelling-investment-don-nicolson-deputy-chairman-1417.html

Continued, No PR firm in the City is going to execute this and I know this from experience. It is down to time, resources and money. The rest of the 12 week plan would run out in a similar fashion and with other deliverables. The whole plan is measureable and quantifiable. Simple metrics like change in share price and increased liquidity. Views on films are easy to see. Eden's image in the retail investor community would be much improved and would not be one whereby Eden is seen as a company that consistently does not deliver on time, it's own defined time. Something that has been labelled at Eden to-date. Eden's image would blossom, interest would be raised, existing shareholders understanding would be qualified and improved, potential investors would understand the true potential for share price returns and Eden would, in my opinion, appear far more dynamic. City investors would be informed, better informed and to a wider audience and can bookmark Eden upon certain criteria for future investment or dabble now. The press could follow the story and build their understanding too until such time as they wanted to deliver an article (PR not investor relations) and therefore Powerscourt's fees paid by Eden would be more productive. Company/investor relationships would be better and I'm pretty sure Eden's share price would be too. NONE of the above takes immense amount of Eden managements time and when its done, its done! How many times does Eden or their PR have to go over the same subjects over and over again with so many different shareholders making so many separate enquiries.

Hello Tony, I will happily answer that for you, but to preface my answer, I will say that my understanding of Eden is that they have circa 2,000 shareholders, many in Eden for many years and at much higher prices than today, that no one in Eden at today's price is making any money and that the share price has been static for nearly two years. No one invests money to leave it idle for two years. 1) The first thing I would do it to create a communications plan. Eden has an operational or business plan. As a listed company they should have a communications plan that addresses all shareholders and potential shareholders so that you reach out to potential new investors. Eden has failed miserably at this and neither Walbrook, nor it would appear Powerscourt has the time, resources or will to create and deliver such a plan. 2) I would deliver much of the content created, on film. Film has grown at a terrific rate, driven by youtube and 68% of those that watch film refer it to a friend. This blends very well with retail investors who do the same with their investments. I would put Sean Smith, Alex Abrey, a Sipcam representative, Michel Villeneuve if possible and our Chairman on film to help deliver the story 3) The plan would be delivered over a 12 week period and would be distributed, primarily by Proactive Investors who specialise in and already have the reach to attract investors. They also land their content on over 250,000 Thompson Reuter terminals in the City for the attention on non-retail investors. Thus, both sides are being addressed. Powerscourt would circulate the same to earn their money, Eden would publish the same on their website, I would email website subscribers to bring it to their attention, place on their twitter account and more. This all helps broaden the reach of Eden and helps to build the story, especially for the likes of Powerscourt with press contacts, Analysts, institutions and more. 4) The content would start from the beginning. It has to for the benefit of potential new investors. So in the introductory films (4 x 12-15 minute films) I would introduce the Company through a series of Q and A, only having the subject on film, part two would introduce the product offering for deeper understanding, part three would address financials and part four be about understanding the significance of the Sipcam deal and focusing on the share price with certain permissible questions The first 4 films would deliver a base understand of who Eden are, what they do, what their markets and opportunities are, where they are financially and how Sipcam works with Eden to hopefully propel them forward. All answers from management, so the horses mouth and this would lay a foundation or a library of information if you will, that doesn't need repeating and that investors can go back to and easily reference over and over again. This is investor relations and it is in my opinion, what Eden needs.

Feeks, No ramping here and most definitely no ramping from Eden. If only they would :) In all serious, Eden has been mute this last 2-3 years. The only thing they have not qualified from a statement they have made was from a late 2017 RNS were they stated they had achieved ' significant commercial success'. Eden simply needs to tell the current story properly, explain the Company to those that do not know it, qualify managements relevance to delivering the opportunity and some insight into the future and update the story thereafter. The above will solidify if not qualify existing shareholders understanding of the Company and their investment. The above will introduce potential shareholders to the current investment and future opportunity. The above will arm Powerscourt to build their story and access their PR targets. The above will enable Powerscourt to softly deliver the Eden Story to Analysts, Institutions and more as it develops without having to sell to them. This should ensure the recipients buy into the story and enquire some more. The above will enable their house broker to feel more confident in their client and to softly share this information with their target audience, again without the need to hard sell Eden and hopefully for that audience to buy into Eden. As the story broadens and the price rises the last two targets will undoubtedly buy in making both Powerscourt's job and the house brokers job much easier. This in turn will help Eden get value for money from these two 'advisers'